RE: RNS - PRELIMINARY RESULTS12 Jul 2022 08:41
Results above expectations ...
12% increase in revenue to £127.4 million (2021: £113.7 million).
· 18% gross margin (2021: 18.3%).
· 24% increase in underlying EBITDA to £6.2 million, excluding £0.2 million in exceptional items (2021: £5.0 million EBITDA).
· Substantial increase in profit before tax to £1.3 million (2021: £0.1 million).
· Cash as at 31 March 2022 of £15.3 million (31 March 2021: £14.8 million).
· Total dividend for the year of 1.00 pence per share (2021: 0.50 pence per share).
· Substantial increase in basic earnings per share to 0.59 pence (2021: 0.17 pence).
· Urgent Care revenue increased by 3.6% to £109.2 million (2021: £105.4 million); 17.8% gross margin (2021: 17.8%).
· Planned Care revenue increased by 43.7% to £7.5 million (2021: £5.2 million); 20.6% gross margin (2021: 23.7%).
· Insourcing revenue increased substantially to £10.3 million (2021: £3.1 million); 17.4% gross margin (2021: 26.8%).
Importantly since 31st March results above ...
Post period highlights
· Multiple contract extensions awarded, underpinning recurring revenue, including:
o Contract extensions, together valued at £19 million, for the management of five UTCs across North West London, awarded to Greenbrook Healthcare Limited ("Greenbrook") and Vocare Limited ("Vocare").
o Vocare awarded three contract extensions to continue to deliver GPOOH services across the North East of England with a total value of c. £4.2 million.
o EFP awarded five-year contract extension for the delivery of on-site gyms for the Royal Mail, valued at a total of £2.5 million.
o Greenbrook awarded a contract extension for the delivery of its virtual consulting service in South-East London valued at £0.4 million, enabling patients who have been directed to a UTC by NHS 111 to see a clinician virtually.
· Final dividend of 0.50 pence per share proposed, bringing total dividend for the year to 1.00 pence per share.
https://twitter.com/surprised_trade/status/1546744141136142337